Aachen, 19th of February 2025 – The organ vitality tech startup Vivalyx has been awarded a €2.5 million grant from the European Innovation Council (EIC) Accelerator, along with a pre-commitment for an additional €6 million in equity investment. This funding will significantly accelerate the market approval of Omnisol – a proprietary, blood-replacing donor organ perfusate.
As part of the two-year project, Vivalyx focuses on obtaining regulatory approval for Omnisol in body-temperature perfusion, a groundbreaking technique to revitalize organs for transplantation. Currently, some organs considered non-transplantable are perfused using donor blood or blood-based products – a method limited in efficacy and scalability due to its reliance on human blood donations. By replacing blood with Omnisol, Vivalyx is paving the way for a scalable, reproducible, and clinically effective solution for organ preservation and revitalization. Moreover, Omnisol has demonstrated significantly better results in preclinical trials compared to blood-based solutions.
Beyond transplantation, Omnisol also holds potential for autotransplantation, where organs are first removed, then perfused and treated before being re-implanted into the same patient. This approach offers promising applications in certain cancer treatments and other complex medical interventions requiring organ therapy.
The funding from the EIC Accelerator will also enable Vivalyx to expand its team, further strengthening clinical and commercial activities.
„This support from the EIC Accelerator is a major milestone for our mission,“ says Dr. Andreas Schumacher, CEO of Vivalyx. „It validates the relevance of our technology and provides the necessary resources to make revitalized organs available to the patients who need them most. We are deeply grateful to the EIC for this funding and to our dedicated team, whose relentless innovation has made this achievement possible.“
About Vivalyx
Vivalyx GmbH was founded in 2022 in Aachen by Dr. Andreas Schumacher, Dr. Benedict Doorschodt, Prof. Dr. René Tolba, PD Dr. Christian Bleilevens, Prof. Dr. Malte Brettel, and Marius Rosenberg. The organ vitality technology startup has developed an innovative technology to revitalize donor organs with the goal of enhancing their viability and increasing the number of available organs for life-saving transplants. The Vivalyx team combines expertise in medicine, medical technology, regulatory affairs, and entrepreneurship and has already attracted prominent investors. For more information, visit https://vivalyx.com.
